Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TPC Versus GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Localized Advanced Nasopharyngeal Carcinoma:Multi Center, Open Label, Randomized Controlled, Non Inferiority Design, Phase III Clinical Study

NCT06561763 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT06561763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06561763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TPC Versus GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Localized Advanced Nasopharyngeal Carcinoma:Multi Center, Open Label, Randomized Controlled, Non Inferiority Design, Phase III Clinical Study
Lead sponsor
Sun Yat-sen University
Phase
Phase 3
Overall status
Not yet recruiting
Start date
August 20, 2024
Completion date
August 20, 2031
Enrollment
416 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

high risk locally advanced nasopharyngeal carcinoma